BRISBANE, Calif., May 6, 2019-- Spiral Therapeutics, a clinical stage pharmaceutical company delivering therapies for hearing loss, today announced the final closing of its Series A financing, bringing the total amount raised in this round to approximately $5.6 million. New investors participating in the second closing included Sunghwan Choi and Inveready. They joined the initial Series A investor syndicate led by Savoir Capital and Camden Partners. "We are pleased to add these key, international investors to an already strong syndicate of Series A investors," said Hugo Peris, founder and CEO of Spiral Therapeutics.